問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間:2023-09-19

王俊隆
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

30Cases

2020-06-01 - 2022-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-10-02 - 2028-01-05

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-16 - 2027-09-09

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2014-09-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin(aerubumab,AR-105)

Participate Sites
11Sites

Terminated10Sites

2016-08-01 - 2018-12-31

Phase III

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
  • Condition/Disease

    carbapenem-resistant Gram-negative bacterial infections

  • Test Drug

    S-649266

Participate Sites
7Sites

Terminated7Sites

2016-01-01 - 2019-05-31

Phase III

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma
  • Condition/Disease

    uncontrolled severe asthma

  • Test Drug

    QAW039

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

許武輝醫師
China Medical University Hospital

Division of Thoracic Medicine

1 2 3